XmAb®819

· Xencor, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XmAb®819, covering 2026-03-05 to 2026-03-05. Get the full timeline:

Most recent: Clinical Trial Update: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma [Phase 1]